Japan Infectious Disease Molecular Diagnostics Market

Japan Infectious Disease Molecular Diagnostics Market Insights Forecasts to 2035

• The Japan Infectious Disease Molecular Diagnostics Market Size was estimated at USD 407.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.62% from 2025 to 2035
• The Japan Infectious Disease Molecular Diagnostics Market Size is Expected to Reach USD 824.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Japan Infectious Disease Molecular Diagnostics Market Size is anticipated to reach USD 824.5 million by 2035, growing at a CAGR of 6.62% from 2025 to 2035. The increasing burden of infectious diseases like HIV, influenza, and COVID, with the high demand for accurate and timely diagnosis, is driving the infectious disease molecular diagnostics market in Japan.  

Market Overview

The Japan infectious disease molecular diagnostics market is the industry for products and technologies, and services used for detecting and identifying pathogens such as bacteria and viruses by analyzing their genetic material or proteins. Infectious disease molecular diagnostics aids in detecting specific sequences in DNA or RNA that may or may not be associated with disease, which ultimately helps in guiding appropriate therapy by identifying specific therapeutic targets for various diseases. There is increased adoption of robust laboratory informatics solutions for automating sample tracking, data collection, and reporting by companies for maintaining efficiency and regulatory compliance, which is accelerating innovation in the market.

Increasing funding from the government and venture capitalists in diagnostic startups that provide molecular diagnostics devices, with increased emphasis on developing new technologies and biomarkers, is offering market growth opportunities. For instance, Craif Inc., a molecular diagnostic company, in April 2025, completed its 2^nd close of its Series C round, bringing total funding for the round to US $22 million. Including grants and debt funding, Craif has raised a cumulative total of approximately US$57 million to date.

Report Coverage

This research report categorizes the market for the Japan infectious disease molecular diagnostics market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan infectious disease molecular diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan infectious disease molecular diagnostics market.

Driving Factors

The market for Japan infectious disease molecular diagnostics is primarily driven by the high demand for accurate and timely diagnosis for guiding effective treatment and controlling disease spread. An increasing prevalence of infectious diseases, along with increasing concerns regarding the increasing mortality rates, especially during the COVID-19 pandemic, has accelerated the market of infectious disease molecular diagnostics. An increasing partnerships and supply agreements among companies for developing advanced solutions in the diagnosis of infectious diseases is supporting the market growth. For instance, in September 2025, Japan’s Hitachi partnered with ELITech for molecular testing for infectious diseases.

Restraining Factors

The inadequate reimbursement scenario is limiting the adoption of innovative diagnostic technologies in cost-sensitive settings, which is challenging for market growth. Further, the presence of a complex regulatory framework associated with the approval process of the devices is hampering the market.

Market Segmentation

The Japan infectious disease molecular diagnostics market share is classified into technology and application.

• The polymerase chain reaction (PCR) segment held the dominant revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan infectious disease molecular diagnostics market is segmented by technology into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), chips & microarrays, and others. Among these, the polymerase chain reaction (PCR) segment held the dominant revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. Polymerase chain reactions (for instance, RT-PCR) are more effective and affordable methods that are revolutionizing DNA and RNA detection with their sensitivity and high-throughput quantification. The widespread application of PCR for detecting a broad range of infectious diseases, and increasing technological advancements like real-time PCR and digital PCR, are propelling the market.

•  The respiratory diseases segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan infectious disease molecular diagnostics market is segmented by application into respiratory diseases, tuberculosis, meningitis, gastrointestinal tract infections, HPV, sexually transmitted infections, and others. Among these, the respiratory diseases segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. There is an increasing case of respiratory illness with the emergence of newer viruses, including adenovirus, parainfluenza, and certain enteroviruses. The high rate of hospitalizations and outpatient visits of patients, especially vulnerable populations like infants and older adults, are contributing to driving the market demand.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan infectious disease molecular diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• Danaher
• QIAGEN
• BD
• bioMérieux SA
• Grifols, S.A.
• Abbott
• F. Hoffmann-La Roche, Ltd.
• Siemens Healthineers AG
• Agilent Technologies, Inc.
• Others

Recent Developments:

• In April 2025, Craif, a molecular diagnostic company that has developed a miRNA-based early cancer detection platform, raised $22M in a series C round to expand US and Japan Operations.

• In November 2024, Japan-based Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 578 million ($4 million) in four projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan Infectious Disease Molecular Diagnostics Market based on the below-mentioned segments:

???????Japan Infectious Disease Molecular Diagnostics Market, By Technology 

• Polymerase Chain Reaction (PCR)
• In Situ Hybridization
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips & Microarrays
• Others

Japan Infectious Disease Molecular Diagnostics Market, By Application

• Respiratory Diseases
• Tuberculosis
• Meningitis
• Gastrointestinal Tract Infections
• HPV
• Sexually Transmitted Infections
• Others

Frequently Asked Questions (FAQs)

1. What is the CAGR of the Japan Infectious Disease Molecular Diagnostics Market over the forecast period?

The Japan Infectious Disease Molecular Diagnostics Market is projected to expand at a CAGR of 6.62% during the forecast period.

2. What is the market size of the Japan Infectious Disease Molecular Diagnostics Market?

The Japan Infectious Disease Molecular Diagnostics Market size is expected to grow from USD 407.5 million in 2024 to USD 824.5 million by 2035, at a CAGR of 6.62% during the forecast period 2025-2035.

3. Who are the 10 top companies operating in the Japan Infectious Disease Molecular Diagnostics Market?

Key players in the Japan Infectious Disease Molecular Diagnostics Market include Sysmex Corporation, Bio-Rad Laboratories, Inc., Danaher, QIAGEN, BD, bioMérieux SA, Grifols, S.A., Abbott, F. Hoffmann-La Roche, Ltd., and Siemens Healthineers AG.

4. What are the main drivers of growth in the Japan Infectious Disease Molecular Diagnostics Market?

The increasing burden of infectious diseases like HIV, influenza, and COVID, high demand for accurate and timely diagnosis, and strategic alliances are the main drivers of growth in the Japan infectious disease molecular diagnostics market.

5. What challenges are limiting the Japan Infectious Disease Molecular Diagnostics Market?

The reimbursement scenario and complex regulatory frameworks remain key restraints in the Japan Infectious Disease Molecular Diagnostics market.

6. What are the latest trends in the Japan infectious disease molecular diagnostics market?

An increasing emphasis on developing new technologies in infectious disease molecular diagnostics is the key trend in the Japan infectious disease molecular diagnostics market.